Insiders who reported open-market trades in the last 12 months at the companies Kevin Charles Gorman files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Julie Cooke - $5.77M in NBIX purchases and sales in the last 12 months
Kyle Gano - $4.87M in NBIX purchases and sales in the last 12 months
Stephen A. Sherwin - $4.13M in NBIX purchases and sales in the last 12 months
Ingrid Delaet - $3.75M in NBIX purchases and sales in the last 12 months
Darin Lippoldt - $3.50M in NBIX purchases and sales in the last 12 months
Jude Onyia - $3.47M in NBIX purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Kevin Charles Gorman is a corporate insider, tracked as Director of NEUROCRINE BIOSCIENCES INC (NBIX). InsiderAlpha holds 12 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Kevin Charles Gorman submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Kevin Charles Gorman been buying or selling stock?
Recorded transactions: 0 open-market purchases and 6 open-market sales ($52.60M) across all tracked filings.
Kevin Charles Gorman is Director of NEUROCRINE BIOSCIENCES INC (NBIX). 12 SEC Form 4 filings on record going back to 2024, most recently on 15 September 2026. Most recent open-market trade: sold $93K of XNCR on 17 June 2026. Lifetime open-market sales: $52.60M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Kevin Charles Gorman.
InsiderAlpha's records for Kevin Charles Gorman go back to 2024: 12 primary Form 4 filings, an average of 4.0 per year. 5 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
